´ó·¢ÁùºÏ²Ê
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Latest news and blogs
News |
Government must free NICE to unlock access to medicines for severe conditions
News |
2024 ´ó·¢ÁùºÏ²Ê Code of Practice launched, with a new constitution and procedure for the PMCPA
Blog |
Understanding medicines access: a look at the severity modifier and its impact
Blog |
Latest Disclosure UK data: higher R&D spend, greater transparency and more partnership with the NHS
Lives Lived Well
From patients and their loved ones to those working within the pharmaceutical industry in the UK, we share a common goal: Lives Lived Well.
The value of industry clinical trials to the UK
Industry clinical trials deliver significant value to the UK economy, the NHS, and the UK’s research and development base.
Accelerating transformation: How to develop effective NHS-industry partnerships
The NHS Confederation and the ´ó·¢ÁùºÏ²Ê have created new guidance on how to create effective NHS-industry partnerships. It was created with the expertise of more than 30 NHS and industry leaders.Ìý
NHS Industry Case Studies Library
Partnerships between the NHS and the pharmaceutical industry benefit patients and the NHS. Visit the ´ó·¢ÁùºÏ²Ê's library of case studies of successful partnerships.Ìý
Events
´ó·¢ÁùºÏ²Ê Industry Summit - Building trust in a time of change
This year sees a whirlwind of change around the world, shaping politics, technology and science as well as the way we communicate and receive information. It has never been more challenging for our industry to build trust and enhance reputation and tell the story of our mission to improve lives and tackle health inequalities.
NICE/DSU/´ó·¢ÁùºÏ²Ê Masterclass: Methods for mapping health utilities for NICE
NICE and the ´ó·¢ÁùºÏ²Ê invite you to the fourth and final event in the NICE/DSU/´ó·¢ÁùºÏ²Ê Masterclass Programme in 2024 – Methods for mapping health utilities for NICE
PMCPA Code of Practice Seminar - SOLD OUT
The training will cover the requirements of the Code of Practice and procedures followed by the PMCPA, the Code of Practice Panel and the Code of Practice Appeal Board.
PMCPA Code of Practice Seminar - SOLD OUT
The training will cover the requirements of the Code of Practice and procedures followed by the PMCPA, the Code of Practice Panel and the Code of Practice Appeal Board.
Key facts and figures for the pharmaceutical industry in the UK
£46.7bn
Turnover [6]
£9bn
investment in UK R&D (more than UKRI’s entire annual budget) [3]
£17.6bn
direct Gross Value Added (GVA) [1]
Key content hubs
The COP28 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ´ó·¢ÁùºÏ²Ê Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.